作者
Ilse De Coster, Isabel Leroux-Roels, Ananda S Bandyopadhyay, Christopher Gast, Kanchanamala Withanage, Katie Steenackers, Philippe De Smedt, Annelies Aerssens, Geert Leroux-Roels, M Steven Oberste, Jennifer L Konopka-Anstadt, William C Weldon, Alan Fix, John Konz, Rahnuma Wahid, John Modlin, Ralf Clemens, Sue Ann Costa Clemens, Novilia S Bachtiar, Pierre Van Damme
发表日期
2021/1/2
期刊
The Lancet
卷号
397
期号
10268
页码范围
39-50
出版商
Elsevier
简介
Background
Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1 and novel OPV2-c2, designed to be more genetically stable than the licensed Sabin monovalent OPV2, have been developed to respond to ongoing polio outbreaks due to circulating vaccine-derived type 2 polioviruses.
Methods
We did two randomised studies at two centres in Belgium. The first was a phase 4 historical control study of monovalent OPV2 in Antwerp, done before global withdrawal of OPV2, and the second was a phase 2 study in Antwerp and Ghent with novel OPV2-c1 and novel OPV2-c2. Eligible participants were healthy adults aged 18–50 years with documented history of at least three polio vaccinations, including OPV in the phase 4 study and either OPV or inactivated poliovirus vaccine (IPV) in the novel OPV2 phase 2 study, with no dose within 12 months of study start. In the historical control trial …
学术搜索中的文章
I De Coster, I Leroux-Roels, AS Bandyopadhyay… - The Lancet, 2021